Skip To Main Content
Yinan Shen on Muck Rack

Yinan Shen

As seen in: Nature, Wiley Online Library, Frontiers, Gut Journal, Science Magazine, Royal Society of Chemistry, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yinan

Contact Yinan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Prediction models for refractory Mycoplasma pneumoniae pneumonia and corticosteroid treatment escalation in hospitalized children: a retrospective cohort study

|
By Yueqian Li, Yinan Shen, Xiao Shi, Yanwei Li, Xuan Li, Junfeng Liu
| Frontiers
Abstract Background: Mycoplasma pneumoniae carries a clinically important risk of a refractory course or the need for intensified corticosteroid therapy. No admission-day prediction tool has been validated to identify children at risk for either outcome. Methods: Children admitted to a single tertiary centre with a diagnosis of MPP between January 2022 and June 2025 were enrolled in a retrospective cohort study.
Open in Who Shared Issue with article?

GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma

|
By Qi Zhang, Qihan Fu, Yinan Shen, Wanyue Cao, Gaowei Jin, Yize Zhang, Jiangchao Wu, Cao Chen, Xingyuan Xu, Ke Sun, Xing Xue, Nick Durham, Mark Cobbold, Yixin Hao, Yi Hong, Jiaqi Huang, Michael Humphries, Gordon Moody, John Stone, Lingyan Sun, Eric Tu, Fei Wang, Yihong Yao, Andy Zou, Xueli Bai, Tingbo Liang, Hongkan Wang, Attilio Bondanza, Daisy Cao, Nina Chu, Benedetto Farsaci, Qijie Jian, Fuzhe Wang
| Nature Verified
Abstract Glypican-3 (GPC3) is highly expressed in hepatocellular carcinoma (HCC), making it an attractive target for chimeric antigen receptor (CAR) T cell therapy; however, this approach has previously shown limited clinical efficacy, potentially owing to high levels of transforming growth factor-β (TGFβ) in the tumour microenvironment1,2,3,4. We therefore engineered CAR T cells with a dominant-negative TGFβ receptor II, which showed enhanced antitumour activity in preclinical studies5.
Open in Who Shared Issue with article?

Integrated Multi-Omics Analysis of Coagulation Dysregulation and Immune Pathway Alterations in 10-Gene Pig-to-Monkey Liver Xenotransplantation: A Case Report

|
By Wei Zhang, Rongrong Wang, Xuan Zhang, Zhiwei Li, Yinan Shen, Min Xu, Xin Duan, Ying Chen, Jie Xiang, Xiaoyuan Zhang, Jinyan Huang, Shunliang Gao, Kaixiang Xu, Xueli Bai, Hongjiang Wei, Tingbo Liang, Yingjiqiong Liang, Huanglei Tang
| Wiley Online Library Verified
1 Introduction End-stage liver disease represents a major global health burden, accounting for approximately two million deaths each year worldwide [1, 2]. Liver transplantation remains the definitive therapeutic option for patients with end-stage liver disease [3]; however, its widespread application is severely constrained by the persistent shortage of suitable human donor organs [4].
Open in Who Shared Issue with article?
See all 8 articles